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Significance statement 32 
Understanding the events in early tuberculosis disease will facilitate the development of novel 33 
tests to predict disease progression and interventions to prevent it.  Blood-based transcriptomic 34 
approaches consistently identify several pathways relevant to clinical disease.  Here we show in 35 
asymptomatic people with HIV infection and early subclinical tuberculosis defined by FDG-36 
PET/CT, that transcripts relating to the classical complement pathway and Fcg-receptor remain 37 
enriched, accompanied by rising levels of circulating antibody/antigen immune complexes.  We 38 
confirm that transcripts relating to these pathways also rise in the 12 months prior to disease 39 
presentation in HIV-uninfected people.  This supports observations that antigen may be present 40 
in early disease despite being paucibacillary, and demonstrates that modulation of the immune 41 
response could occur via immune complex formation.  42 
 43 
 44 
 45 
 46 
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Abstract  47 
The transition between latent and active tuberculosis (TB) occurs prior to symptom onset.  Better 48 
understanding of the early events in subclinical disease will facilitate the development of 49 
diagnostics and interventions that improve TB control.  This is particularly relevant in the 50 
context of HIV-1 co-infection where progression of TB is more likely.   51 
 52 
In a recent study using [18F]-fluoro-2-deoxy-D-glucose positron emission/computed tomography 53 
(FDG-PET/CT) on 35 asymptomatic, HIV-1 infected adults we identified ten participants with 54 
radiographic evidence of subclinical disease, significantly more likely to progress than the 25 55 
participants without. To gain insight into the biological events in early disease we performed 56 
blood-based whole genome transcriptomic analysis on these participants and 15 active TB 57 
patients.  We found transcripts representing the classical complement pathway and Fcg receptor-58 
1 overabundant from subclinical stages of disease.  Levels of circulating immune 59 
(antibody/antigen) complexes also increased in subclinical disease and were highly correlated 60 
with C1q transcript abundance.  To validate our findings, we analyzed transcriptomic data from a 61 
publicly available dataset where samples were available in the 2 years prior to TB disease 62 
presentation.  Transcripts representing the classical complement pathway and Fcg receptor-1 63 
were also differentially expressed in the 12 months prior to disease presentation.   64 
 65 
Our results indicate that levels of antibody/antigen complexes increase early in disease, 66 
associated with increased gene expression of C1q and Fcg receptors that bind them.  67 
Understanding the role this plays in disease progression may facilitate development of 68 
 4 
interventions that prevent this leading to a more favorable outcome and may also be important to 69 
diagnostic development. 70 
 71 
/body 72 
Introduction 73 
Conventionally, tuberculosis (TB) is divided into stages of asymptomatic latent infection, during 74 
which bacillary replication is effectively controlled in a healthy host, and active disease in which 75 
this has failed, resulting in symptomatic deterioration. Understanding the transition between 76 
these two states is important, although until recently this has been over-looked (1). Active 77 
disease is usually defined by a combination of symptoms, pathology (radiographically or 78 
histologically identified) and culturable bacilli. These features do not appear simultaneously but 79 
develop over time and may be intermittently present, hence the active disease processes may 80 
begin months before symptom onset i.e. as subclinical active disease (2). In some of those who 81 
initially reactivate, disease progression may be arrested and regress particularly when disease 82 
extent is limited(3). A greater understanding of the early events in disease is critical for the 83 
development of novel approaches to both identify people in early subclinical stages of disease 84 
and interventions to prevent progression.  This is of particular importance in those with HIV-1 85 
co-infection where TB disease progression is more likely.  However, studying the natural history 86 
of TB in this group is further complicated by the imperative to provide preventive therapy, so 87 
novel approaches are needed. 88 
 89 
In macaques the failure of the granuloma has been shown to be followed by cellular infiltration 90 
within bronchi (pneumonia)(4). In human autopsy studies pneumonic infiltration has also been 91 
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observed as the first pathological sign of pulmonary disease(5). Disease regression and self-92 
healing of lesions is associated with fibrosis, however, it appears that disease risk following this 93 
is significantly increased(6). Medical imaging is a key approach to detecting evidence of early 94 
disease in asymptomatic persons, facilitated by a characteristic distribution of pathology. Chest 95 
radiography (CXR) has long been used for this purpose, however, CXR has limitations in both 96 
sensitivity and reproducibility(7). [18F]-fluoro-2-deoxy-D-glucose positron emission/computed 97 
tomography (FDG-PET/CT) is a highly sensitive imaging modality, which combines cross-98 
sectional anatomical detail from a CT scan with quantitation and localization of metabolic 99 
activity by quantifying uptake of FDG (a glucose analogue) by PET scan. FDG uptake in 100 
tuberculosis is related to activated macrophages and an inflammatory infiltrate at the site of 101 
disease(8). In a recent clinical study, we utilized FDG-PET/CT to identify evidence of early 102 
disease in asymptomatic people otherwise conventionally considered to have latent infection 103 
(QuantiFERON Gold in-tube (QF-GIT) positive, sputum culture negative, CXR no evidence of 104 
active disease) but at high risk of disease progression as HIV-1 infected, anti-retroviral therapy 105 
naïve. Of the 35 people scanned 10 (28.6%) had evidence of subclinical disease by FDG-106 
PET/CT and they were significantly more likely to progress to clinical disease(2). 107 
 108 
Transcriptomic profiling of peripheral blood has provided critical insight into active TB (9-12). 109 
Blankley et al have recently analyzed 16 such studies and shown overall findings in modular 110 
analysis of the transcriptome to be remarkably consistent. Meta-profiling identified 380 genes 111 
differentially abundant in active TB in at least 9 of the 16 studies.  Based on pathway analysis 112 
they then determined the main functional groups of genes in active TB to relate to; Interferon 113 
signaling/inducible genes, the complement pathway, immunoglobulin receptors, recognition of 114 
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pathogen associated molecular patterns, inflammasome and pro-inflammatory pathways, (13, 115 
14).  However, it is not clear which of these processes occur at the earliest stages of disease.  116 
Understanding such host-pathogen interaction in early disease may provide insight that could 117 
facilitates novel approaches to diagnose and manage subclinical disease.  Zak et al have recently 118 
demonstrated in HIV-1 uninfected adolescents that transcriptional differences are present in 119 
blood months prior to clinical patency suggesting that transcriptomic profiling of peripheral 120 
blood might be a useful approach to provide insight into subclinical disease.     121 
 122 
In the present study, we utilized the cohort of HIV-1 infected adults described above in which 123 
presence or absence of subclinical TB was defined by FDG-PET/CT(2) and co-recruited control 124 
participants with active TB. We investigated which components of the active TB whole blood 125 
transcriptional profile were present in those with evidence of subclinical disease to provide 126 
insight into the biology underlying early progressive disease.  127 
 128 
Results  129 
Details of the clinical and radiographic features of the clinical cohort have been previously 130 
described(2). Thirty-five asymptomatic, healthy, HIV-1 infected, ART naïve participants with 131 
median CD4 count of 517/mm3, a positive QFN-GIT and no previous history of TB, were 132 
screened for active TB by two sputum cultures (induced if needed) and CXR. All participants 133 
were of African ancestry resident in Khayelitsha (township of Cape Town, South Africa). 134 
Following 42-day negative sputum cultures, participants were confirmed as remaining symptom 135 
free, underwent FDG-PET/CT and were commenced on isoniazid preventive therapy. FDG-136 
PET/CT scans were systematically analyzed, with abnormalities categorized and spatially 137 
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mapped, interpreted in the context of historical autopsy studies and then classified as being 138 
consistent with subclinical active TB or not. Ten of the 35 participants were classified as having 139 
subclinical active TB, due to either infiltrates and/or fibrotic scars (n = 9 – consistent with 140 
bronchogenic spread of disease) or multiple active nodules (n = 1 – consistent with 141 
haematogenous spread of disease) on FDG-PET/CT (referred to as “subclinical TB”); the 142 
remaining 25 participants had no evidence of disease activity on FDG-PET/CT scan (referred to 143 
as “latent TB”). Four out of 10 participants with evidence of subclinical TB were determined to 144 
have disease progression (defined as developing TB symptoms along with radiographic 145 
deterioration or culture positivity) requiring commencement of standard TB therapy in contrast 146 
to 0/25 participants with no evidence of subclinical TB. Participants were followed up for 6 147 
months, 27 of 35 participants (six subclinical and 21 latent) then had repeat FDG-PET/CT. All 148 
six of the subclinical participants had improvement in baseline abnormalities in lymph nodes and 149 
lung parenchyma in contrast to only 1/21 of those without evidence of subclinical TB. Three 150 
participants (2 in subclinical group and 1 in the latent group) had been commenced on 151 
antiretroviral therapy during follow up as CD4 count fell below 350/mm3, in accordance with 152 
local standard of care at the time of recruitment. 153 
In addition, we recruited 15 participants with symptomatic, microbiologically confirmed 154 
pulmonary TB (referred to as “active TB”) for blood sampling.  There were no significant 155 
differences between those with active, subclinical and latent TB with regard to median age 156 
(p=0.41), sex (p=0.52) or median CD4 count (p=0.09).  Conversely, median viral load (VL) and 157 
median C-reactive protein (CRP) were significantly different between active and latent TB 158 
(p<0.0001 and p=0.0001; respectively), but not between subclinical and latent TB (p=0.97 and 159 
p=0.08 respectively) (SI Appendix, Figure S1). 160 
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 161 
Eighty-two transcripts distinguish subclinical and active TB from latent TB 162 
Transcript abundance in whole blood RNA was determined by Illumina HumanHT-12 v 4.0 163 
Expression BeadChips microarray. We initially defined a set of transcripts that were 164 
differentially abundant between latent and active TB to determine a transcriptional profile of 165 
active TB.  From the 47,231 probes on the microarray, 18,919 were present in at least 10% of 166 
samples (see methods). The 18919 transcripts were then statistically filtered (ANOVA with 167 
Benjamini Hochberg FDR correction (pcorr < 0.05) to identify 2573 transcripts showing 168 
significant differential abundance between the different stages of TB.  From these transcripts, we 169 
identified 893 transcripts with at least a 1.5-fold difference in abundance between active and 170 
latent TB. To determine which of these transcripts might be relevant to early disease, we filtered 171 
the 893 transcripts by fold change to identify those differentially abundant between subclinical 172 
and latent TB. As disease pathology in subclinical TB is of minimal extent by comparison with 173 
active TB, we reasoned that the relevant transcripts may be expressed in blood at lower levels in 174 
comparison to active TB and hence both 1.25 and 1.5-fold change cut offs were used resulting in 175 
a 203 and 82-transcript list respectively (SI Appendix, Figure S2 and Supp. Excel sheet).   176 
 177 
Hierarchical clustering was then performed on the 893, 203 and 82 transcripts which confirmed 178 
progressive improvement in ability to classify those with subclinical TB from those with latent 179 
TB while clustering them with active TB (Figure 1a). Two participants with subclinical TB did 180 
not cluster with active TB, one with multiple active nodules consistent with haematogeous 181 
spread of disease and the other who, of those with abnormalities consistent with bronchogenic 182 
spread, had the smallest infiltrate with amongst the lowest metabolic activity in lesion or lymph 183 
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node by FDG uptake (SI Appendix, Table S1).  In 27 participants seen at 6-month follow-up 184 
after receiving either IPT or standard TB therapy the subclinical and latent groups became 185 
indistinguishable by transcriptional signature (Figure 1b).   186 
  187 
To examine if abundance of these transcripts altered as subclinical disease activity increased we 188 
investigated the association of metabolic activity by FDG uptake with transcript abundance. 189 
Participants with subclinical TB were further divided into two categories; five participants 190 
showing intense FDG uptake (Visual score (VS) =3) within lung parenchyma or central lymph 191 
nodes and five participants with less intense FDG uptake (VS=0-2) (SI Appendix, Table S1). 192 
Hierarchical clustering using the group mean expression values for the 82-transcripts 193 
demonstrated that the subclinical participants with greater metabolic activity, clustered more 194 
closely with active TB than the subclinical TB group with low FDG uptake, which in turn 195 
clustered closer to the latent TB group (Figure 1c).  This was then further demonstrated by 196 
disease risk score (determined for each participant by subtracting the summed normalized 197 
expression values of under-abundant transcripts from that of over-abundant transcripts as 198 
described in (12)) (Figure 1d). There was no significant difference in mean C-reactive Protein 199 
(CRP) (2.62 mg/L vs 2.88 mg/L; p=0.85 – Normal range <5 mg/L), white cell count (WCC) 200 
(5.72 x109/L vs 5.77 x109/L; p=0.97 – Normal range 4.5-11 x109/L) or Log (HIV VL 201 
(copies/mL)) (4.29 vs 4.36; p=0.86) between the participants with subclinical TB as high or low 202 
metabolic activity on PET/CT.  203 
 204 
To evaluate if HIV-1 viral load contributed the observed differential abundance between TB 205 
disease states in the 82-transcript signature, we performed multiple regression using TB status 206 
(latent, subclinical, active) and HIV viral load as explanatory variables for expression score. TB 207 
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status but not HIV VL was significantly associated (r2=0.75, p<0.0001; TB status, coef=55.9, 208 
p<0.001; HIV VL, coef=9.18, p=0.08).  209 
The 893, 203 and 82 transcripts mapped to 678, 181 and 72 genes respectively, of these 174, 39 210 
and 17 genes respectively are present in the 380 meta-gene signature for active TB, identified by 211 
Blankley et al as being present in at least 9 other studies hence consistently associated with 212 
TB(13), (SI Appendix, Table S2 and Supp. Excel sheet).  213 
 214 
Classical complement pathway transcripts are overabundant in subclinical disease and correlate 215 
with the concentration of circulating immune complexes 216 
To identify biological processes common to subclinical and active TB, pathway analysis was 217 
performed on the three transcript signatures (893, 203 and 82). In the 893-transcript active TB 218 
signature showed complement and interferon signaling to be the most enriched canonical 219 
pathways (each, p=0.0002), followed by death receptor signaling and JAK family kinase in IL-6 220 
signaling (Figure 2a). Of these, only complement remained over-represented in the 203 and 82-221 
transcript signatures (p=0.0001 and p=0.006 respectively) suggesting that complement may be 222 
relevant in early active disease. Using only the 174, 39 and 17 genes common to the 380-meta 223 
signature this pattern was retained with complement remaining the most enriched pathway in all 224 
3 gene lists (SI Appendix, Figure S4)    225 
 226 
Predominantly components of the classical complement pathway (complement component 1q 227 
subcomponent B (C1QB), serpin peptidase inhibitor member 1 (SERPING1), complement 228 
component 2 (C2) and complement component 5 (C5)) were overabundant in the blood of 229 
subclinical and active TB patients compared to those with latent TB (Figure 2b). Of these 230 
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C1QB, SERPING1 and C2 are all in the 380-metasignature derived by Blankley et al, with 231 
C1QB and SERPING1 being overabundant in active TB for 15 of the 16 studies analyzed. 232 
To further investigate the role of complement in subclinical TB, we next evaluated the 233 
relationship between serum concentration of complement proteins C1q, SERPING1 and C5 and 234 
their whole blood transcript abundance using paired samples. There was no correlation between 235 
serum concentration and transcript abundance for C1q (rs=-0.08, p=0.59), SERPING1 (rs=0.02, 236 
p=0.89) or C5 (rs=0.16, p=0.29) (Figure 3a, c, e).  Because the classical complement pathway is 237 
triggered by C1q binding of antibody/antigen immune complexes(15), we next evaluated the 238 
relationship between transcript abundance of C1QB and serum concentration of circulating 239 
immune complex (CIC – antibody/antigen complexes)  as determined by a C1q binding assay.  240 
Transcript abundance of C1QB in whole blood was significantly correlated with CIC (rs=0.48, 241 
p=0.0005) as was SERPING1 (rs=0.46, p=0.0008) but not C5, where a trend was observed albeit 242 
not significant (rs=0.26, p=0.08) (Figure 3b, d, f).  As both TB and HIV can contribute to levels 243 
of CIC we performed multiple regression by TB status (latent, subclinical, active) and HIV viral 244 
load as explanatory variables for CIC.  TB status but not HIV VL had a significant association 245 
(r2=0.26, p=0.001; HIV VL, coef=0.10, p=0.25; TB status, coef=0.31, p=0.008).   246 
 247 
We next evaluated the relationship between CIC and metabolic activity in subclinical TB 248 
classifying participants as having low or high metabolic activity as above. CIC was significantly 249 
increased across different TB disease states (p=0.0004), post hoc analysis controlling for false 250 
discovery demonstrated that those with active TB (p=0.0001, q=0.0002) and those with 251 
subclinical TB and high metabolic activity on PET/CT (p=0.038, q=0.04) had higher serum 252 
concentration of CIC than latent TB (Figure 3g).  Furthermore serum CIC as a single marker to 253 
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discriminate the four individuals subsequently treated for TB during follow-up from the 31 254 
individuals that were not, showed an AUC of 0.754.  A cut off of 192 µg Eq/ml had sensitivity of 255 
75% and specificity of 93.6% and correctly classified 91.4%.  Of note the only participant of the 256 
four subsequently treated for active TB with a serum CIC less than 192 µg Eq/ml had a different 257 
radiographic presentation subclinical disease, with multiple nodules suggestive of 258 
haematogenous spread in contrast to the bronchogenic pattern of disease seen in the remainder.   259 
  260 
In addition to binding C1q, antibody/antigen immune complexes also bind Fcg receptors and Fcg 261 
Binding Protein (FCGBP). Those with subclinical TB and active TB also had relative 262 
overabundance of transcripts relating to the Fc fragment of IgG, high affinity I receptor (CD64) 263 
(FCGR1) with FCGR1A/B/C all being present in the 82 and/or 203 transcript list, however there 264 
was a reduction in abundance of FCGBP (Figure 2c  and SI Appendix, Table S2).  FCGR1A, 265 
FCGR1B and FCGBP were all present in the 380 meta-signature.  FCGBP is the most 266 
consistently underabundant transcript in active TB identified in 14 previous studies.  By contrast 267 
FCGR1B and FCGR1A are amongst the most consistently overabundant transcripts in active TB 268 
being present in 16 and 14 studies respectively. RT-PCR was also conducted using primers for 269 
FCGR1C, FCGBP, C1QB and SERPING1 which confirmed the differences demonstrated by 270 
microarray between latent, subclinical and active TB (SI Appendix, Figure S3).   271 
 272 
Classical complement and interferon signaling pathways are increased in progressive TB in HIV 273 
uninfected persons   274 
To validate our findings and establish if classical complement and Fc gamma receptor gene 275 
activation were important in early TB disease, we reanalyzed the RNA sequencing data from the 276 
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publically available dataset from the study reported by Zak et al, in which, samples were 277 
available in the 2 years prior to disease presentation with appropriate non-progressor 278 
controls(16). Although no accurate subclinical disease phenotype was ascertained, we reasoned 279 
that those in the 6 to 12 months prior to disease presentation may have had subclinical disease. 280 
Furthermore, participants in Zak et al were all HIV uninfected allowing us to determine whether 281 
our findings were generalizable. To investigate the biological processes relevant to progressing 282 
disease, we first established the number of transcripts significantly differentially abundant (pcorr 283 
<0.05) and with >1.5FC overabundance between progressors and non-progressors at <180 days, 284 
181-360 days, 361-540 days and 541-720 days prior to disease presentation, identifying 362, 285 
154, 3 and 3 genes respectively (see methods and Supp. Excel sheet). We then conducted IPA 286 
analysis for the <180 day and 181-360 time points. The complement pathway was the second and 287 
third most significantly enriched canonical pathway at 181-360 days (p=5.80x10-5 (11.1% of 288 
pathway, p=5.80x10-5) and <180 days prior to presentation (p=6.02x10-7 (19.4% of pathway, 289 
p=6.02x10-7) respectively, with the interferon signaling pathway the most significantly enriched 290 
at these time points (Figure 4). In keeping with our initial results, the classical complement 291 
pathway was largely responsible for this with C1QB/C, SERPING1 and C2 all significantly 292 
differentially expressed at both time points and C5 and C1QA also significantly differentially 293 
expressed <180 days before presentation. In addition, FCGR1A/B/CP were all amongst the most 294 
significantly differentially expressed genes between progressors and non-progressors at both 295 
time points (all in top 22 genes for both) (Figure 4). 296 
 297 
Interferon signaling transcripts are increased in both untreated HIV and active TB   298 
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Enrichment of the complement pathway was observed in early TB disease states in both HIV-299 
infected and un-infected persons, however, enrichment of interferon signaling was less 300 
prominent in HIV-associated TB.  We further explored this by undertaking a modular analysis of 301 
the whole blood transcriptome in HIV and active TB.  Modules are groups of co-regulated 302 
transcripts subsequently categorized into functional groups through unbiased literature review.  303 
The principles informing this approach have been previously published (17). Using this 304 
approach, the modular profile of active TB has been previously shown to be remarkably 305 
consistent across 16 studies (13).   306 
 307 
For this analysis, in addition to the HIV-1 infected, ART naïve participants with symptomatic 308 
active pulmonary TB (HIV+ART-TB+; n=15) and with no evidence of active TB (HIV+ART-309 
TB-; n=25, i.e. excluding the 10 with subclinical active TB), we recruited HIV uninfected 310 
participants with symptomatic, active, pulmonary TB (HIV-TB+; n=14) and with no evidence of 311 
active TB (HIV-TB-; n=15). We also recruited HIV-1 infected participants established on ART 312 
fully with viral load fully suppressed and no evidence of active TB (HIV+ART+TB-; n=8).  All 313 
these additional participants were also resident Khayelitsha and of African ancestry.  314 
 315 
18,751 transcripts were “present” in at least 10% of samples and included in the modular 316 
analysis, using HIV-TB- participants as the primary control group. The average transcript 317 
abundance for each module was determined for each participant.  Of the 260 modules previously 318 
characterized, 38 had functional roles determined and analysis was restricted to these modules, 319 
three of these modules relate to interferon signaling.  320 
 321 
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By comparison HIV-TB- participants, participants with untreated HIV only (HIV+ART-TB-) 322 
had significant differences (after correcting for false discovery) in modular expression in 8/38 323 
modules (5 increased expression and 3 reduced expression), those with TB only (HIV-TB+) had 324 
significant differences in expression in 24/38 modules (15 increased expression and 9 reduced 325 
expression) (SI Appendix, Table S3).  Both the HIV only group and TB only group had 326 
significantly increased expression in all three interferon modules.  Those with HIV-associated 327 
TB (HIV+ART-TB+) had greater expression of the interferon modules in comparison to those 328 
with HIV or TB only (Figure 5 and SI Appendix, Table 3).  Those with HIV but on ART 329 
(HIV+ART+TB-) with fully suppressed viral load showed normalization of expression within 330 
the interferon modules and had no significant differences in any of the 38 modules in comparison 331 
to HIV-TB- controls.  Given the background increased abundance of interferon related 332 
transcripts in HIV infected persons not on ART it is likely that any increases expression within 333 
these pathways in early tuberculosis would be less discriminatory.       334 
 335 
Recognizing that interferons are well known to enhance expression of Fcg receptor we next 336 
sought to establish the effect of interferon on expression of complement components.  We cross-337 
referenced the 36 genes comprising the Ingenuity IPA complement canonical pathway against 338 
the Interferome database, a database of interferon regulated genes (IRG) from a variety of 339 
experimental settings (http://www.interferome.org/interferome/home.jspx).  All human data on 340 
IRG were from in vitro experiments, we restricted analysis to studies on human blood and genes 341 
showing > 2-fold increase following interferon stimulation.  Of the 36 genes, 9 (25%) had 342 
evidence of increased expression on interferon stimulation; C1QA/B/C, C2, CFB, CR1, CR2, 343 
ITGAX SERPING1. While abundance of some of these potentially interferon regulated 344 
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complement components were enriched in tuberculosis others were not, in addition C5 did not 345 
have experimental evidence of interferon regulation.  Furthermore overall abundance of 346 
transcripts relating the to the TB relevant complement and FCGR1 components (C1QA/B/C, 347 
SERPING1, C2, C5, FCGR1A/B/C) while significantly increased in TB, was not significantly 348 
affected by HIV status (two-way ANOVA with TB and HIV as explanatory variables of disease 349 
risk score; r2 0.58, TB p<0.0001 and HIV p=0.12) with discriminatory ability of these transcripts 350 
for TB in both HIV infected and uninfected persons excellent (disease risk score; HIV infected - 351 
AUC 0.997, HIV uninfected – AUC 0.938) (SI Appendix, Figure S5).  It is therefore unlikely 352 
that the complement pathway member upregulated in TB merely reflect interferon responsive 353 
genes.  354 
 355 
To establish if this pattern of complement and FCGR transcript expression was seen in other 356 
diseases we analysed the dataset (GEO dataset- GSE42834) of Bloom et al in which participants 357 
with active TB, active sarcoid, non-active sarcoid, lung cancer, pneumonia and healthy controls 358 
had whole blood transcriptional profiling undertaken(18).  We profiled transcript abundance of 359 
the 81 complement and FCGR transcripts (62 transcripts relating to the 36 complement genes in 360 
the IPA database and all 19 FCGR transcripts on the platform).  19 of 81 transcripts showed 361 
greater than 2-fold difference in transcript abundance in at least one of the disease categories 362 
when compared to healthy controls.  In initial hierarchical clustering of disease groups for these 363 
19 transcripts showed active TB clustered with active sarcoid, and community-acquired 364 
pneumonia clustered with lung cancer (SI Appendix, Figure S6).  We then performed K-means 365 
clustering (3 clusters, 50 iterations, Euclidean distance metric) to provide an unbiased assessment 366 
of the pattern of transcript abundance across the different diseases.  One cluster contained 367 
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transcripts showing greatest abundance in tuberculosis over other diseases included C1QB, 368 
SERPING1, FCGR1A, FCGR1B and FCGR1C.  The cluster containing transcripts showing 369 
greatest abundance in diseases other than tuberculosis (particularly pneumonia and lung cancer) 370 
included CR1, ITGAM, ITGAX, C3AR1, FCGR2A and FCGR3B.  The final cluster contained 371 
FCGRBP as a single transcript that was under abundant in tuberculosis, community-pneumonia 372 
and lung cancer in comparison to control.  These data support our findings of complement and 373 
FCGR expression in tuberculosis, demonstrated in other cohorts presented in the paper and also 374 
re-emphasis, that complement component expression is not simply a function of interferon 375 
stimulation or a generic inflammatory signal.     376 
    377 
Discussion  378 
We have previously shown that in a subgroup of asymptomatic, HIV-1 infected persons, 379 
conventionally diagnosed with latent TB, evidence of subclinical disease can be identified 380 
utilizing high resolution imaging (FDG-PET/CT) which is not apparent by routine clinical 381 
screening.  Those with evidence of subclinical disease on FDG-PET/CT were also found to be 382 
more likely to progress clinically and to require treatment for active TB (2). In this study we 383 
have identified components of the active TB whole blood transcriptional response that are also 384 
present in subclinical disease and shown that circulating immune complexes rise during 385 
subclinical disease. 386 
 387 
Previous transcriptional studies have consistently indicated several key pathways in active TB 388 
(interferon signaling/inducing genes, inflammasome/pro-inflammatory pathways, recognition of 389 
PAMP, the complement pathway and immunoglobulin receptors) but these studies have not been 390 
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able to dissect the biological processes that may occur at the outset of disease. We determined 391 
that a subset of transcripts in the whole blood transcriptional response to symptomatic active TB 392 
were relevant to subclinical disease and that these transcripts were enriched for the classical 393 
complement pathway and immunoglobulin receptors (FCg receptor 1), suggesting a cellular 394 
response to antibody-antigen complexes may occur early in disease.  This was supported by our 395 
finding that CIC in serum increased in relation to TB disease status and was highly correlated 396 
with transcript abundance of C1q.  Furthermore, with increasing metabolic activity of subclinical 397 
disease the transcriptional response aligned more closely with active TB and levels of CIC 398 
increased. Importantly the abundance of these transcripts and levels of CIC did not show any 399 
significant relationship with HIV viral load.   400 
 401 
We validated our findings utilizing the publicly available data reported by Zak et al (16).  While 402 
subclinical disease was not characterized by imaging, regular samples were available up to 2 403 
years prior to clinical disease presentation in HIV uninfected persons.  Of note in contrast to our 404 
study, Zak et al also excluded participants who developed TB within 6 months of enrolment in 405 
the training set and 3 months of enrolment in the validation set.  Our analysis confirmed that 406 
transcripts relating to the classical complement pathway and immunoglobulin receptors increased 407 
during the 12 months prior to disease presentation in HIV uninfected persons.  However, in 408 
addition interferon signaling pathways also appear to increase in this population.  Whilst 409 
interferon-signaling pathways were prominent in our 893-transcript signature differentiating 410 
active from latent TB in HIV infected persons they became less prominent as this signature was 411 
filtered to allow better distinction of subclinical TB from latent TB.  We showed that untreated 412 
HIV infection itself leads to increases in interferon related transcripts in whole blood.  Hence, the 413 
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finding that the interferon signaling pathway transcripts were less discriminatory in early disease 414 
in those with untreated HIV is likely due to the high background level of these transcripts in this 415 
population.  We also showed that the pattern of complement and FCGR expression varied in 416 
different pulmonary diseases.  While the pattern of expression in tuberculosis was also seen in 417 
active sarcoidosis though at a lower level of expression, a different pattern of expression was 418 
seen in community-acquired pneumonia and lung cancer where expression of C3 binding 419 
receptors was more prominent.  Tuberculosis and sarcoidosis have previously been shown to 420 
have many similarities in whole blood transcriptional profile(18, 19). 421 
 422 
Transcripts relating to the classical complement pathway (in particular, C1Q and SERPING1) 423 
and Fcg Receptor 1 are amongst the most consistently overabundant in active TB and FCGBP as 424 
the most consistently underabundant supporting their role in early disease.  Cliff et al also 425 
reported that transcripts relating to the complement pathway decrease within the first week of 426 
treatment for active TB(20). This suggests that the abundance of transcripts relating to the 427 
complement pathway may mark a rising antigen load rising early in disease, falling rapidly with 428 
treatment.  CIC has frequently been reported to be elevated in active tuberculosis, increasing 429 
with extent of disease and reducing with treatment, CIC have been shown to contain secreted TB 430 
antigens (e.g. 38kDa and 30kDa (Ag85)) and non-secreted antigens (e.g. 16kDa (HspX)) (21, 431 
22).  In addition to opsonisation and complement activation, antibodies have an additional 432 
functional role in regulating the immune response through interaction with innate cells via a 433 
variety of Fc Receptors which may directly affect effector mechanisms and clearance of the 434 
pathogen (23-25).          435 
 436 
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Hunter et al investigated the histological appearances of early pulmonary TB in humans in 437 
several studies.  They demonstrated that the earliest feature of disease is a lipid-rich pneumonia 438 
in which alveoli are filled with foamy macrophages with CD4 cells present at significantly lower 439 
frequency than in the granuloma. They also observed large clusters of B-cells bordering this 440 
region. Very few acid-fast bacilli (AFB) are visible at this stage but abundant mycobacterial 441 
antigen is evident on immunohistochemical staining. As necrosis develops within the pneumonia 442 
there is then a marked increase in numbers of AFB (26-28).  Increased concentration of both 443 
38kDa TB antigen and 38kDa specific IgG have been identified in bronchoalveolar lavage 444 
samples of TB patients(29).  445 
 446 
Based on our findings we propose that at this early stage of disease, the increase in 447 
mycobacterial antigen concentration results in an increased concentration of antibody-antigen 448 
complexes increases at the site of disease.  This may lead to increased expression of components 449 
of the classical complement pathway in recruited cells (to facilitate the targeted delivery of 450 
complement) and up-regulation of Fcg receptor on monocytes and neutrophils to promote 451 
phagocytosis, as we have observed.  By contrast expression of FCGBP is reduced.  FCGBP has 452 
been shown to be the most consistently underabundant gene in active compared to latent TB but 453 
little is known about its function.  Kobayashi et al have shown that Fcg Binding Protein is 454 
present in sputum as well as other bodily secretions and that it inhibits activation of classical 455 
complement pathway(30).  Its reduction in TB disease may therefore facilitate C1q binding of 456 
immune complexes promoting complement activation.   457 
 458 
 21 
Formation of immune complexes in disease has both beneficial and detrimental effects for the 459 
host and the complement system can both promote and mitigate immunopathology. Immune 460 
complex aggregates that precipitate and persist within the lung are likely to be damaging through 461 
C3a/C5a mediated neutrophil recruitment increasing inflammation and tissue necrosis which 462 
may promote bacillary multiplication(31).  It has been suggested that solubilization and diffusion 463 
of immune complexes away from tissue via extracellular fluid and the systemic circulation for 464 
clearance by mononuclear phagocytic system is critical to minimize local inflammation and 465 
tissue damage (32, 33).  This appears to be facilitated by rapid C1q initiation of the classical 466 
complement pathway and C3b deposition which results in reduction in the size of the immune 467 
complex aggregates to maintain solubility, deficiencies in classical complement components 468 
reduce immune complex solubility and increase risk of immune complex mediated autoimmune 469 
diseases (32, 33).  It is possible, therefore, that the increased expression of classical complement 470 
components in tuberculosis is directly in response to increased production of immune complexes 471 
at the site of disease to allow localized delivery of C1q to inhibit the precipitation of immune 472 
complexes and minimize lung damage.  Although, our insight has been informed by analysis of 473 
blood, Cai et al demonstrated that C1q mRNA and protein levels were greater at the site of 474 
disease (in pleural fluid and bronchoalveolar lavage fluid) compared to blood in active pleural 475 
and pulmonary tuberculosis (34).   476 
 477 
We found that although abundance of classical complement components correlated with 478 
circulating immune complexes they did not correlate well with serum levels of the proteins they 479 
encode.  There are several possible explanations of this.  For blood cells migrating to the disease 480 
site, expression as well as consumption of complement may occur locally.  In addition, 481 
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complement components may also be bound to immune complexes whereas the assay would 482 
only measure unbound complement proteins.  Furthermore, whole the blood transcriptome 483 
predominantly reflects mRNA expression in leukocytes whereas circulating complement proteins 484 
are manufactured within the liver and by a number other cell types (e.g. epithelial and 485 
endothelial cells) affecting the correlation of whole blood RNA and serum protein(35).            486 
 487 
There are limitations of this study.  We used a broad definition of subclinical disease which 488 
grouped together several distinct abnormalities found to be consistent with early disease, with 489 
reference to historical autopsy studies. Our sample size was modest and participants often had a 490 
combination of abnormalities and hence we were unable to tease out transcriptional differences 491 
between participants with potentially different disease pathogenesis.  For example, there may be 492 
differences between those presenting with multiple nodules suggestive of haematogeneous 493 
spread of disease in comparison to disease spreading bronchogenically which may be interesting 494 
the characterize. Larger studies will be needed explore this in greater detail and further validate 495 
findings.  In addition, we used peripheral blood to investigate pathogenesis of disease, while this 496 
approach is widely adopted, confirmation of our findings is needed in samples from site of 497 
disease. Our study was conducted in ART naïve, HIV infected participants with well-preserved 498 
CD4 counts with validation in HIV uninfected adolescents, confirmatory studies in other 499 
populations are required. Furthermore, although we demonstrated that CIC rises in relation to 500 
disease state in tuberculosis. This may have a role as a biomarker for identification of subclinical 501 
disease, however further studies will be needed confirm these findings in independent cohorts.  502 
 503 
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Our results indicate that the abundance of transcripts relating to the classical complement 504 
pathway and Fcg receptors is increased from early disease in both untreated HIV infected adults 505 
and HIV uninfected adolescents in contrast to transcripts related to interferon signaling which 506 
appear less discriminatory in untreated HIV infected people.  This will be an important 507 
consideration in the development of universal transcript-based biomarkers that are predictive of 508 
disease.  Our findings support the observation that in early disease, though paucibacillary, 509 
antigen may still be present.  This may have the potential to modulate the immune response by 510 
forming antibody complexes that initiate the complement pathway and bind Fcg receptors 511 
upregulated on cells. However further studies will be needed to clarify in TB, how immune 512 
complexes form, their composition and the role they play in early disease.  Developing a greater 513 
understanding of the early events in TB disease will be important to future TB control efforts.  514 
Not all those who initially reactivate latent infection and develop evidence of early subclinical 515 
disease will go on to develop symptomatic clinical disease, as regression will occur in a 516 
proportion.  Determining the factors that govern progression or regression of disease will allow 517 
us to develop rational interventions that may lead to more favorable outcomes and prevent 518 
disease.  519 
 520 
Materials and Methods 521 
Recruitment of participants  522 
Ethical approval for this study was provided by the research ethics committees of the University 523 
of Cape Town (013/2011) and Stellenbosch University (N12/11/079).  Recruitment and 524 
classification of participants whose samples were utilized for this study have been described in 525 
detail previously(2).  Briefly all participants and controls were HIV-1 infected adults, who were 526 
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ART naïve and resident in Khayelitsha, a peri-urban township of Cape Town, South Africa 527 
where >95% of people are of Xhosa origin.  Recruitment took place between 2011 and 2013, TB 528 
incidence at the time of the study was >1,000/100,000.  All consent documents were provided to 529 
potential participants in English or Xhosa and read through with a member of the study team to 530 
ensure full understanding and capacity to consent before signing.  Participants recruited to 531 
undergo PET/CT were recruited in a 2-stage process.  At initial screening consent they were 532 
provided with an information leaflet in English or Xhosa explaining the study procedures and the 533 
risks and benefits of study involvement.  At the end of the screening period this leaflet was 534 
explained in detail with eligible participants and any queries or concerns addressed prior to final 535 
consenting for study entry.  536 
   537 
The 35 asymptomatic participants undergoing FDG-PET/CT had blood sampling for RNA 538 
(Tempus, Thermo Fisher Scientific, Waltham, MA) and serum on the day of scan prior to 539 
receiving any IPT.  The 15 HIV-1 infected controls with symptomatic, microbiologically 540 
confirmed pulmonary tuberculosis that were age, sex and CD4 matched to the 35 asymptomatic 541 
participants undergoing FDG-PET/CT and had blood sampling for RNA and serum within 24 542 
hours of commencing TB treatment but did not undergo FDG-PET/CT. 543 
Additional participants were recruited as controls for modular analysis.  All were resident in 544 
Khayelitsha. All participants were of African ancestry (almost entirely of Xhosa origin).  545 
Symptomatic HIV-1 infected and HIV-1 uninfected participants with active TB had their 546 
diagnosis confirmed by either a positive sputum culture for Mtb or a positive sputum GeneXpert 547 
TB-RIF (Cepheid, Sunnyvale, CA), sputum smear status was also established.  Blood sampling 548 
of active TB controls was carried out before, or within 24 hours, of treatment commencing.  549 
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HIV-1 infected participants on ART were established on medication for > 6 months and had a 550 
suppressed viral load (<40 copies/mL or lower than detectable limit). Participants were 551 
diagnosed HIV-1 infected if they had documented evidence of a positive point of care (POC) test 552 
for HIV-1 in their medical notes and, either a positive HIV-1 viral load and/or a positive 553 
confirmatory HIV-1 ELISA.  HIV-1 uninfected participants had a documented negative POC test 554 
for HIV-1.  HIV-1 uninfected adults with no evidence of active TB were the main control group 555 
for comparison.   556 
 557 
RNA extraction 558 
Three mL of blood was drawn into Tempus Blood RNA tubes and shaken vigorously for 10-15 559 
seconds.  Tempus tubes were stored within 6 hours of sampling in a freezer between 20oC and -560 
80oC for no longer than 21 months before RNA extraction.  RNA was extracted using the 561 
PerfectPure™ Blood RNA Kit (5 PRIME) according to maufacturer’s instructions.  RNA 562 
integrity was assessed using the Bioanalyser Nano Assay (Agilent, Santa Clara, CA) with all 563 
samples having RNA integrity number (RIN) 7-9.5.  RNA yield was assessed using a Nanodrop 564 
ND 1000 spectrophotometer (Thermoscientific, Waltham, MA) and RNA yield was suboptimal 565 
for a single sample (active TB control) that was not analysed.   566 
Two thousand nanograms of the isolated total RNA was globin reduced using the Human 567 
GLOBINclear™ Kit (Ambion, Austin, TX) according to manufacturer’s instructions.  200ng of 568 
globin-reduced RNA was then used to prepare and amplify biotinylated, antisense 569 
complementary RNA (cRNA) with the TotalPrep RNA Amplification Kit (Illumina, San Diego, 570 
CA).  750ng of labelled cRNA was then hybridized overnight to Illumina HumanHT-12 v 4.0 571 
Expression BeadChips containing 47,231 probes.  Samples were randomly distributed across 572 
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chips along with control samples to minimize chip related bias.  The arrays were washed, 573 
blocked, stained and scanned on an Illumina HiScan, as per manufacturer’s instructions.  Signal 574 
intensity values were then generated on Genomestudio (Illumina). 575 
 576 
Microarray data analysis 577 
Raw background subtracted expression data was normalized using GeneSpring GX version 12.6 578 
(Agilent).  For each sample, probes were assigned a signal intensity detection p-value in 579 
comparison to background hybridization and probes were assigned a “present” flag using a 0.99 580 
cut off.  Raw signal values <1 were then set to a threshold of 1 and all values were log2 581 
transformed.  To minimize technical variation, each sample was then normalized using a 75th 582 
percentile shift algorithm in which the log2 transformed intensity value corresponding to the 75th 583 
percentile was subtracted from log2 transformed intensity value for each probe within a sample.  584 
Baseline transformation was then carried out to rescale intensity values to the median of all 585 
samples.  Samples were visualized using principal component analysis (PCA) to confirm no 586 
outliers.  Following this probes that were not “present” in at least 10% of samples were filtered 587 
out before further analysis.   588 
 589 
Pathway analysis was conducted on gene lists using Ingenuity Pathway Analysis (IPA) software 590 
(Qiagen Bioinformatics, Hilden, Germany).  The canonical pathways in IPA are well-591 
characterized metabolic and cell signaling pathways based on the available scientific literature.  592 
The strength of association between gene lists and pathways was determined by Fisher’s exact 593 
test.   Where hierarchical clustering was used to visualize data, Pearson uncentered (cosine) 594 
distance metric and average linkage rule was used.   595 
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 596 
Modular analysis of the transcripts was undertaken.  Modules are groups of co-regulated 597 
transcripts subsequently categorized into functional groups through unbiased literature review.  598 
The principles informing this approach have been previously published (17) as have the specific 599 
details of the modules used in this study along with complete transcript lists (36).  Extensive 600 
functional analysis of these modules using a variety of analytic approaches are available through 601 
the following link http://www.biir.net/public_wikis/module_annotation/V2_Trial_8_Modules).  602 
The average transcript abundance for each module was determined for each participant.  Of the 603 
260 modules, 38 had functional roles determined and analysis was restricted to these modules.  604 
HIV-1 uninfected adults with no evidence of active TB were used as the primary control group.  605 
The Simes-Benjamini-Hochberg method was used to control for false discovery rate (FDR) in 606 
analysis of modules 607 
 608 
The raw and normalized microarray data has been deposited in GEO (GSE69581).  All data 609 
collected and analyzed in the experiments adhere to the Minimal Information About a 610 
Microarray Experiment (MIAME) guidelines. 611 
 612 
RNA sequence data analysis from Zak et al 613 
Sequencing data was downloaded from NCBI GEO repository with project number 614 
PRJNA315611. Metadata was provided in GEO repository and supplementary data of associated 615 
publication(16).  93 samples were available from progressors.  Per protocol time to TB was used 616 
to categorise each sample as being taken <180 days, 181-360 days, 361-540 days, 541-720 days, 617 
>720 days prior to diagnosis or being taken after diagnosis.  Samples taken after diagnosis or 618 
more than 720 days before diagnosis were not included in analysis leaving 72 samples from 619 
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progressors across four timepoints.  In order to allow for determination of differentially 620 
expressed genes at each of the four timepoints, four groups of non-progressors were assigned in a 621 
1:1 ratio ensuring matching by time from recruitment (see Supp Excel sheet).  All sequence data 622 
were quality checked with FastQC (version 0.11.5) before being aligned to the human genome 623 
(NCBI GRCh38.p10 build) using STAR (version 2.5.2b) with default parameters. Gene counting 624 
of the position-sorted aligned reads was done using HTSeq-count (version 0.6.1p1) with the 625 
default union mode. All genes with <1 reads on average across all samples were filtered out from 626 
expression analysis. Read count normalisation and differential gene expression analysis was 627 
done using DESeq2 in R (37) and the fold change and false discovery rate corrected significance 628 
(adjusted p-value) for each gene between progressors and non-progressors are reported.  629 
 630 
RT-PCR arrays 631 
RNA extracted from whole blood used for the microarrays was reverse transcribed using the RT2 632 
First Strand Kit (Qiagen, Hilden, Germany) which includes a genomic DNA (gDNA) elimination 633 
step. cDNA was analysed using 384-well RT2 Profiler Custom PCR Arrays (Qiagen, Hilden, 634 
Germany) on the Roche 480 platform. The arrays included 4 house keeping (HK) genes (HPRT1, 635 
B2M, RPLP0, HSP90AB1), three control reactions to monitor gDNA contamination and reverse 636 
transcription efficiency, and the genes of interest (including C1QB, FCGBP, FCGR1, 637 
SERPING1). Delta Ct (ΔCt) was calculated according to the average Ct of the 4 HK genes. Delta 638 
delta Ct (ΔΔCt) was calculated as the sample ΔCT-Median ΔCT of all samples, and fold change 639 
was calculated as 2^(-ΔΔCt). Log2 normalised fold change values (mean=0, variance=1) were 640 
plotted as box plots in Qlucore Omics explorer. 641 
 642 
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Serum analysis 643 
Blood was drawn into 5mL SSTTM II Advance tubes (BD Diagnostics, Franklin Lakes, NJ), 644 
transported to the laboratory and centrifuged at 1200g for 10 minutes.  The serum was aliquoted 645 
and stored at -80oC.  Two of 15 active TB participants had no serum available. All 35 646 
participants that underwent FDG-PET/CT had serum available.  Analytes were measured by 647 
ELISA:  SerpinG1 (Cusabio, Wuhan, China), Circulating Immune complex (Bühlmann, Bremen, 648 
Germany), C1q (Abcam, Cambridge, UK), C5 (assay measures uncleaved C5 and C5a) (Abcam, 649 
Cambridge, UK). ELISA plates were read on a Bio-Rad iMark microplate reader (Bio-Rad, 650 
Hercules, CA, USA) with standard curves generated for each analyte. Values that were below 651 
manufacturer determined minimal detectable limit or the minimum asymptote of the standard 652 
curve were assigned a zero value.  653 
 654 
Statistical Analysis 655 
Apart from microarray data where analysis was conducted primarily in GeneSpring GX version 656 
12.6 (Agilent) and by Ingenuity Pathway Analysis software (Qiagen) as described above, 657 
statistical analysis of continuous and categorical variables, correlation analysis and data 658 
visualization was conducted in Stata ver. 12.1 (StataCorp) and Prism ver. 7.0c (GraphPad 659 
software). The normality of data was assessed by the Shapiro-Wilk test and variance compared 660 
by F-test or Bartlett’s test.  Non-parametric data was compared using the Mann-Whitney U test 661 
or the Kruskal Wallis test and parametric data compared using t-test or ANOVA. Two-stage 662 
linear step-up procedure of Benjamini, Krieger and Yekutieli was to control for false discovery 663 
rate following Kruskal Wallis test if needed. Correlation was performed by Spearman rho or 664 
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Pearson’s test depending on distribution of data. Proportions were compared by χ2 test or 665 
Fisher’s exact test (if the contingency included a number £ 5).   666 
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Figure Legends 836 
 837 
Figure 1  838 
Statistical and fold change filtering reveals 82 transcripts that separate active and 839 
subclinical TB from latent TB   840 
a. Heatmaps showing hierarchical clustering (Pearson Uncentered (cosine) distance metric and 841 
average linkage rule) for the 893, 203 and 82 transcript signatures.  Active TB (n=15, red), 842 
Subclinical TB (n=10, orange), Latent TB (n=25, blue), showing increasing clustering of 843 
subclinical TB with active TB and increasing separation of subclinical TB from latent TB (with 844 
no subclinical pathology). 845 
 846 
b. 2D-PCA plot showing effect of treatment on 82 transcripts.  Left panel shows pre-treatment, 847 
with separation seen between subclinical TB (n=10) represented as orange squares and latent TB 848 
(with no evidence of subclinical pathology) (n=25) as blue squares.  In the right panel post 849 
treatment (for 27 of 35 participants) those with previous subclinical TB (n=6) (orange triangle) 850 
cluster with latent TB (n=21) (blue triangles).  851 
 852 
c.  Subclinical TB cases with higher metabolic activity on FDG-PET/CT clustered more closely 853 
with active TB.  Participants with subclinical TB (n=10) were subclassified into those with low 854 
intensity FDG uptake within lung parenchymal or mediastinal lymph nodes (Visual Score 0-1 – 855 
FDG uptake less than or equal to mediastinal blood pool, Yellow – n=5) or high intensity uptake 856 
(Visual Score 3 – FDG uptake greater than mediastinal blood pool, Orange – n=5).  Participants 857 
with active TB (n=15) are shown in Red and with latent TB (n=25) in Blue.  Heatmap (c) 858 
 43 
represents average expression within the 4 groups for each of the 82-transcripts and shows 859 
hierarchical clustering (Pearson Uncentered (cosine) distance metric and average linkage rule).  860 
Participants with subclinical TB and high intensity FDG uptake were more closely related to 861 
Active TB.   862 
 863 
d. A Disease risk score was determined for each participant using the 893, 203 and 82 transcripts 864 
by subtracting the summed normalized expression values of under-abundant transcripts from that 865 
of over-abundant transcripts (see (12)).  A dot plot was used to visualize differences between the 866 
groups  867 
 868 
Figure 2  869 
Transcripts relating to the classical complement pathway are overabundant in  870 
subclinical and active TB. 871 
a. Top 4 enriched canonical pathways listed by significance (p<0.05, Fisher’s exact) for the 893-872 
transcript signature of active TB shown.  The bar chart shows the proportion of these pathways 873 
represented in the 893, 203 and 82-transcript signatures. 874 
 875 
b. Schematic of the complement pathway, created using Ingenuity Pathway Analysis software, 876 
showing components of the pathway with overabundant transcripts in active (n=15) and 877 
subclinical TB (n=10) compared to latent TB (n=25) (in pink).  Box and whisker plots show 878 
normalized expression of complement components SERPING1 and C1QB (part of 82-transcript 879 
signature) and C2 and C5 (part of 203- transcript signature) by TB disease state.  880 
 881 
 44 
c. Box and whisker plots show normalized expression of immunoglobulin related transcripts 882 
FCGBP and FCGR1C (part of 82-transcript signature) and FCGR1A and FCGR1B (part of 203- 883 
transcript signature) by TB disease state. 884 
 885 
Figure 3  886 
Correlation of transcript abundance with serum concentration of complement components 887 
and Circulating Immune Complex 888 
a-f. Scatter plots showing correlation of transcript abundance against serum concentration of 889 
protein product with Spearman rho and p-value for; (a) C1QB transcript abundance vs C1q 890 
serum concentration, (b) C1QB transcript abundance vs serum circulating immune complex 891 
(CIC) concentration, (c) SERPING1 transcript abundance vs. SERPING1 serum concentration, 892 
(d) SERPING1 transcript abundance vs serum CIC concentration, (e) C5 transcript abundance vs 893 
C5 serum concentration, (f) C5 transcript abundance vs serum CIC concentration.  Correlation 894 
was calculated for 48 participants with serum samples (13 active TB (as 2 of 15 participants did 895 
not have serum available), 10 subclinical TB and 25 latent TB).  For graphs b, d and f, a single 896 
outlier with serum circulating immune complex concentration below detectable limit is not 897 
shown.    898 
 899 
g. Dot plot with median and IQR showing the CIC level for participants with latent, subclinical 900 
(low activity), subclinical (high activity) and active TB.  CIC was significantly increased across 901 
different TB disease states (p=0.0004 - Kruskal Wallis), post hoc analysis controlling for false 902 
discovery by Two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli 903 
demonstrated that those with active TB (p=0.0001, q=0.0002) and those with subclinical TB and 904 
 45 
high metabolic activity on PET/CT (p=0.038, q=0.04) had higher serum concentration of CIC 905 
than latent TB   906 
 907 
Figure 4 908 
Complement and Fc Gamma receptor genes significantly differentially expressed between 909 
progressors and non-progressors from Zak et al 910 
Analysis of RNAseq data for HIV uninfected persons who eventually progressed to TB in 911 
comparison to matched non-progressors from Zak et al.  Genes with <1 read on average across 912 
all samples were filtered out with expression analysis therefore conducted on 25,518 genes (see 913 
methods).  892 genes were significantly differentially abundant (pcorr<0.05) between progressors 914 
0-180 days prior to diagnosis and matched non-progressors, of which 362 were also >1.5 fold 915 
overabundant.  610 genes were significantly differentially abundant (pcorr<0.05) between 916 
progressors 181-360 days prior to diagnosis and matched non-progressors, of which 154 were 917 
also >1.5 fold overabundant.  IPA pathway analysis was conducted on these gene lists.   918 
 919 
a. Top 4 enriched canonical pathways listed by significance (p<0.05, Fisher’s exact) for the 362 920 
genes and 154 genes differentially abundant at 0-180 and 181-360 days prior to diagnosis.  The 921 
bar chart shows the proportion of these pathways represented.   922 
 923 
b. Dot plots showing gene abundance (as normalized read counts) in progressors in 180 day 924 
blocks prior to disease presentation in comparison to 1:1 matched non-progressors (labeled 1-4 925 
see methods and Supp Excel sheet)).  All components of the complement pathway or Fc gamma 926 
receptor within the group of significantly differentially abundant at either <180 days or 181-360 927 
 46 
days before diagnosis are shown.  Significance shown by asterisk; pcorr <0.05(*), <0.01(**), 928 
<0.001(***), <0.0001(****) (see Supp Excel sheet for exact values) 929 
 930 
Figure 5  931 
Comparison of modular transcript abundance by TB and HIV status 932 
a – Radar plots depicting fold change in transcript abundance in comparison to median modular 933 
transcript abundance in control group (HIV- TB-) for 29 modules.  Plot on left shows fold 934 
change of median modular transcript abundance for HIV+ART-TB- (green), HIV- TB+ (red), 935 
HIV+ART- TB+ (blue) and HIV+ART+TB- (pink) in comparison to HIV-TB- controls (black) 936 
overlaid on same graph   Plots on right show fold change for each individual participant in the 937 
four groups in comparison to control (HIV- TB-) with the median value in bold.  Log2 scale.. 938 
See also Supp table 3. 939 
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